QUICK SPARK: Moderna Stock Drops 25%, Eyes Worst Day in Company's History

SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Summit Therapeutics' partner Akeso announced positive phase III HARMONi-GI1 study results showing ivonescimab plus chemotherapy achieved superior overall survival compared to AstraZeneca's Imfinzi plus chemotherapy in advanced biliary tract cancer patients. The drug also met key secondary endpoints for progression-free survival and objective response rate. These results strengthen ivonescimab's development case beyond its initial NSCLC focus into colorectal and genitourinary cancers.

Moderna Borrows $2 Billion To Expand Oncology Business

Moderna announces a $2 billion convertible senior note offering to fund its oncology business growth and strategically manage debt.

EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer

Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.

Mike Johnson Says Prescription Drug Prices Are at 'Lowest Levels' in 60 Years, Credits Trump and Republicans for Lower Costs

Johnson credits Trump and Republicans for record low drug prices, stating Americans are seeing lower costs and more money in their pockets.

Dolly Parton Life of Philanthropy May Have Kept Singer From Billionaire Status: ‘I Don’t Work for Money, Never Did’

Dolly Parton left a lasting legacy across music, TV, film and entertainment. The singer also leaves behind a lifetime of philanthropy.

Moderna Says FDA Approved sBLAs For 2026-2027 Spikevax And mNEXSPIKE Formulas Targeting JN.1-Lineage XFG Subvariant; Says Vaccines Expected Available In Coming Days